Effects of olmesartan-based treatment on masked, white-coat, poorly controlled, and well-controlled hypertension: HONEST study

Journal of Clinical Hypertension

Volumn 16, Issue 6, 2014, Pages 442-450

  Kario, Kazuomi ^a   Saito, Ikuo ^b   Kushiro, Toshio ^c   Teramukai, Satoshi ^d   Ishikawa, Yusuke ^e   Kobayashi, Fumiaki ^e   Shimada, Kazuyuki ^f  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Life Planning Center Foundation   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e DAIICHI SANKYO CO   (Japan)

^f Shin Oyama City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL PRACTICE; DRUG EFFECT; ELEVATED BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; OBSERVATIONAL STUDY; POORLY CONTROLLED HYPERTENSION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WELL CONTROLLED HYPERTENSION; WHITE COAT HYPERTENSION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TIME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MASKED HYPERTENSION; MIDDLE AGED; OLMESARTAN MEDOXOMIL; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; WHITE COAT HYPERTENSION;

EID: 84902376096     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12323     Document Type: Article

References (30)

1. Kario K, Eguchi K, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation. 2003;108:e72-e73.
2. Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. Hypertens Res. 2007;30:479-488.
3. Obara T, Ohkubo T, Kikuya M, et al. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan Home versus Office Measurement Evaluation Study. Blood Press Monit. 2005;10:311-316.
4. Sobrino J, Domenech M, Camafort M, et al. Prevalence of masked hypertension in a cohort of controlled hypertensive patients in Spain. Med Clin (Barc). 2011;136:607-612.
5. Shimada K, Fujita T, Ito S, et al. The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res. 2008;31:1903-1911.
6. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291:1342-1349.
7. Hara A, Ohkubo T, Kondo T, et al. Detection of silent cerebrovascular lesions in individuals with 'masked' and 'white-coat' hypertension by home blood pressure measurement: the Ohasama study. J Hypertens. 2009;27:1049-1055.
8. Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA. 1988;259:225-228.
9. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens. 2005;19:801-807.
10. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.
11. Franks PW. White-coat hypertension and risk of stroke: do the data really tell us what we need to know? Hypertension. 2005;45:183-184.
12. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232.
13. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
14. Kario K, Ishikawa J, Pickering TG, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29:581-587.
15. Saito I, Kario K, Kushiro T, et al. Rationale, study design, baseline characteristics, and blood pressure at 16 weeks in the HONEST study. Hypertens Res. 2013;36:177-182.
16. Kario K, Saito I, Kushiro T, et al. Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks. J Hum Hypertens. 2013;27:721-728.
17. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
18. Kario K, Sato Y, Shirayama M, et al. Inhibitory effects of azelnidipine tablets on morning hypertension. Drugs R D. 2013;13:63-73.
19. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505-1526.
20. Kawabe H, Saito I. Reproducibility of masked hypertension determined from morning and evening home blood pressure measurement over a 6-month period. Hypertens Res. 2007;30:845-851.
21. Ishikawa J, Kario K, Eguchi K, et al. Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) study. Hypertens Res. 2006;29:679-686.
22. Obara T, Ohkubo T, Funahashi J, et al. Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J Hypertens. 2005;23:1653-1660.
23. Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing white-coat effect. Am J Hypertens. 2008;21:153-158.
24. Palatini P, Winnicki M, Santonastaso M, et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension. Hypertension. 2004;44:170-174.
25. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005;165:1541-1546.
26. Saito I, Kushiro T, Hirata K, et al. The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan. J Clin Hypertens (Greenwich). 2008;10:272-279.
27. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3:283-291.
28. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23:419-430.
29. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.
30. Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension. Hypertens Res. 2012;35:750-755.